Prof Ola Landgren speaks to ecancer about minimal residual disease (MRD) in multiple myeloma.
Initially, he discusses the clinical relevance of the depth of response in multiple myeloma. He explains how depth of response correlates with prolonged survival.
Prof Landgren further discusses the difference between MRD negativity and CR and explains how these endpoints provide different information and which is more valuable clinically.
He also talks about the use of MRD negativity in clinical practice and the evolving clinical role of MRD negativity in the near future. He says that in the future, MRD negativity may be the gold standard of depth of response outcomes, and the ultimate goal of treatment in select groups of patients.
Prof Landgren mentions that it's important to maximise efficacy in early lines of therapy (e.g. NDMM*) as patients may not live to experience 2nd or 3rd line therapy. As MRD negativity is currently the best predictor of long-term outcomes, making MRD negativity a goal of therapy is critical for achieving the best outcome for patients. He also discusses the role of MRD negativity in the RRMM* setting.
Prof Landgren concludes by explaining whether MRD negativity rates achieved in clinical trials should be taken into consideration for treating patients with NDMM and RRMM.
|Clinical relevance of depth of response in multiple myeloma|
|The clinical importance and difference between MRD negativity in MM and complete response|
|The use of MRD negativity in clinical practice|
|The future of the clinical role of MRD negativity|
|Should achieving MRD negativity be a treatment goal for NDMM and RRMM patients?|
|Choosing regimens for patients by considering the MRD negative rates achieved in clinical trials|
MAT-GLB-2200112 (v1.0) – 02/2022
*NDMM = Newly diagnosed multiple myeloma
*RRMM = Relapsed / refractory myeloma
ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.